Breast Cancer Clinical Trials in Bethesda, Maryland

16 studies are recruiting for breast cancer in Bethesda, Maryland right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases

    Background: Breast cancer is the most common cancer among women. It can often spread to the liver, lungs, bones, or brain. Breast cancer that spreads to the brain is often fatal. Researchers want to know if tumor DNA found in spinal fluid, blood, or tumor tissue can help predict when the cancer wil…

    Stage
    Not phased
    Ages
    18 to 120
    Site
    National Institutes of Health Clinical Center, Bethesda, Maryland
    Run by
    National Cancer Institute (NCI)

    See if you can join NCT07619534 on ClinicalTrials.gov

  2. Genomic Services Research Program

    Background: Genes are the instructions a person s body uses to function. Genome sequencing reads through all of a person s genes. Everyone has many gene variants, and most do not cause disease. Some gene variants called secondary findings may be important for a person s health even if they are not …

    Stage
    Not phased
    Ages
    0 to 105
    Site
    National Institutes of Health Clinical Center, Bethesda, Maryland
    Run by
    National Human Genome Research Institute (NHGRI)

    See if you can join NCT02595957 on ClinicalTrials.gov

  3. Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

    This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with es…

    Stage
    Phase 3
    Ages
    18 to 60
    Site
    Walter Reed National Military Medical Center, Bethesda, Maryland
    Locations
    1261 in total
    Run by
    NRG Oncology

    See if you can join NCT05879926 on ClinicalTrials.gov

  4. Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

    This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor [Retifanlimab], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metastatic or locally recurrent breast cancer (aMBC) patients with no…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    The Center for Cancer and Blood Disorders a division of American Oncology Partners, P.A., Bethesda, Maryland
    Locations
    79 in total
    Run by
    BriaCell Therapeutics Corporation

    See if you can join NCT06072612 on ClinicalTrials.gov

  5. Collection of Blood From Patients With Cancer

    This study will collect blood from patients with cancer to study the level of cells which decrease the immune response (suppressor cells) before and after chemotherapy. Patients 18 years of age and older with cancer may participate. This study does not involve treatment. Participants will have abou…

    Stage
    Not phased
    Ages
    18 and older
    Site
    National Institutes of Health Clinical Center, Bethesda, Maryland
    Run by
    National Cancer Institute (NCI)

    See if you can join NCT00034216 on ClinicalTrials.gov

  6. Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis

    Background: - Some genes may be associated with a greater chance of side effects during cancer treatment. These genes may also make certain treatments less effective. Researchers want to collect blood or cheek swab samples from people having cancer treatment to study these genes. Objectives: - To o…

    Stage
    Not phased
    Ages
    3 and older
    Site
    National Institutes of Health Clinical Center, Bethesda, Maryland
    Run by
    National Cancer Institute (NCI)

    See if you can join NCT01441089 on ClinicalTrials.gov

  7. Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

    Background: A person s tumor is studied for mutations. When cells are found that can attack the mutation in a person s tumor, the genes from those cells are studied to find the parts that make the attack possible. White blood cells are then taken from the person s body, and the gene transfer occurs…

    Stage
    Phase 2
    Ages
    18 to 72
    Site
    National Institutes of Health Clinical Center, Bethesda, Maryland
    Run by
    National Cancer Institute (NCI)

    See if you can join NCT03412877 on ClinicalTrials.gov

  8. A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast)

    Background: Breast cancer is the most common cancer in US women. There are different types of breast cancers; some are aggressive and difficult to treat. Researchers want to know if an algorithm (ENLIGHT) can help choose approved drugs that will treat these cancers more effectively. Objective: To t…

    Stage
    Not phased
    Ages
    18 to 120
    Site
    National Institutes of Health Clinical Center, Bethesda, Maryland
    Run by
    National Cancer Institute (NCI)

    See if you can join NCT07067138 on ClinicalTrials.gov

  9. Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers

    Background: In a new cancer therapy, researchers take a person s blood, select a certain white blood cell to grow in the lab, and then change the genes of these cells using a virus. The cells are then given back to the person. This is called gene transfer. For this study, researchers will modify th…

    Stage
    Phase 1
    Ages
    18 to 72
    Site
    National Institutes of Health Clinical Center, Bethesda, Maryland
    Run by
    National Cancer Institute (NCI)

    See if you can join NCT02830724 on ClinicalTrials.gov

  10. Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery

    This trial is to investigate if in patients with clinically node positive breast cancer undergoing upfront surgery, treatment with TAS and ART is superior to ALND in terms of arm-related Quality of Life (QoL) and occurrence of lymphedema two years after randomization.

    Stage
    Not phased
    Ages
    18 and older
    Site
    Walter Reed National Military Medical Center, Bethesda, Maryland
    Locations
    54 in total
    Run by
    University Hospital, Basel, Switzerland

    See if you can join NCT07140172 on ClinicalTrials.gov

  11. Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies

    This study aims to provide long-term follow-up care of patients previously enrolled in a vaccine study that involved poxviral vectors. Vectors are sequences of genetic material that can be used to introduce specific genes into genetic makeup. The study does not involve the use of any drug or biolog…

    Stage
    Not phased
    Ages
    18 and older
    Site
    National Institutes of Health Clinical Center, Bethesda, Maryland
    Run by
    National Cancer Institute (NCI)

    See if you can join NCT00451022 on ClinicalTrials.gov

  12. Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

    This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib and palbociclib plus endocrine therapy for the treatment of patients with locally advanced or metastatic HR+/HER2- advanced breast cancer.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    American Oncology Partners, P.A., Bethesda, Maryland
    Locations
    203 in total
    Run by
    Celcuity Inc

    See if you can join NCT06757634 on ClinicalTrials.gov

  13. A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

    The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. HR-positive breast cancer cells have proteins on their surface called…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Maryland Oncology Hematology P.A., Bethesda, Maryland
    Locations
    202 in total
    Run by
    Pfizer

    See if you can join NCT07062965 on ClinicalTrials.gov

  14. EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)

    The EXActDNA-003 study will prospectively enroll participants who are planning to undergo chemotherapy for high-risk, early breast cancer, who are willing to provide tissue and blood specimens for circulating tumor DNA (ctDNA) analysis. Participants will be followed for up to 5.5 years.

    Stage
    Not phased
    Ages
    18 and older
    Site
    The Center for Cancer and Blood Disorders - Bethesda, Bethesda, Maryland
    Locations
    58 in total
    Run by
    Exact Sciences Corporation

    See if you can join NCT06401421 on ClinicalTrials.gov

  15. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

    Stage
    Not phased
    Ages
    Any age
    Site
    Massive Bio SYNERGY-AI site, Bethesda, Maryland
    Locations
    68 in total
    Run by
    Massive Bio, Inc.

    See if you can join NCT03452774 on ClinicalTrials.gov

  16. MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

    The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry, which is intended to enabl…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Maryland Oncology Hematology - Bethesda, Bethesda, Maryland
    Locations
    134 in total
    Run by
    Agendia

    See if you can join NCT03053193 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.